Betaglue Technologies
Last verified 2026-05-02. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $33.6Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2024-04-01attributed |
| Founded | 2009 |
| Headquarters | Milan, Italy |
| Industry | biotech |
| Stage | unknown |
| Website | betaglue.com |
BetaGlue Therapeutics develops targeted nuclear medicine for solid tumors, led by YntraDose, an Yttrium-90 microsphere radiotherapy delivered directly into the tumor. It serves cancer patients with hard-to-treat solid tumors such as locally advanced pancreatic cancer and hepatocellular carcinoma. Its interventional approach concentrates radiation inside the tumor to spare healthy tissue compared with external-beam radiotherapy.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-04-01 | grant | $2.7M | undisclosed |
Detected tech stack
WordPress 7.0, Yoast SEO 27.4, reCAPTCHA, jQuery Migrate 3.4.1, PHP, cdnjs, Contact Form 7 6.1.5, Python, Cloudflare, MySQL, jquery 3.7.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $33.6M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | betaglue.com, read 2026-05-02 |
| Description | self-reported | betaglue.com, read 2026-05-02 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.